Amneal Pharmaceuticals AMRX is leaning into a playbook that can work in multiple market backdrops. The company is pairing ...

Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for ...

The industry is entering “the golden era for biosimilars,” Amneal co-CEO Chirag Patel said Wednesday morning as he explained ...

AMRX targets 2027 upside through biosimilars scale, new complex launches, and Specialty recovery after 2026 Rytary erosion ...

Samsung Bioepis Co., Ltd. today released its Second Quarter 2026 Biosimilar Market Report, marking the thirteenth edition of the Quarterly Biosimilar Market Report in the United States (US). The ...

Rheumatologist Marcus Snow, MD, is comfortable with prescribing biosimilars as a first-line, first-time biologic, and discussing them with patients. "If a biosimilar is on the market, it has gone ...

As of March 2026, the number of approved biosimilars in the United States had reached 92 across 20 unique biological molecules, of which 73% had been launched in the market.

The biosimilars market in the United States is poised to experience significant growth in the coming year and beyond, driven—in part—by greater uptake and an acceleration in FDA approvals and product ...

LAS VEGAS—Optum Rx is planning to add up to three biosimilar drugs to its formulary to compete directly with AbbVie's Humira, which accounts for massive pharmacy spend each year. Optum Rx, the ...

A 10-year push for more biosimilars in the U.S. has led to a surge in copycat entrants, bringing more attention to the legal ...

January 31 is set to mark the start of a watershed year for the biosimilars industry with the release of Amjevita, the first biosimilar for Humira, the world’s best-selling drug. Several more Humira ...